PT-141

Overview

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that acts as an agonist of the melanocortin 3 and 4 receptors (MC3R and MC4R). It is the only FDA-approved treatment that works through the central nervous system to address sexual desire — a mechanism fundamentally different from phosphodiesterase-5 (PDE5) inhibitors like sildenafil, which act on peripheral vascular tissue.

PT-141's development traces back to Melanotan II research in the 1990s at the University of Arizona. During clinical trials of Melanotan II (an alpha-melanocyte-stimulating hormone analog originally developed for UV-free tanning), researchers observed significant pro-sexual effects in study participants. PT-141 was subsequently derived from Melanotan II by removing the amino acid sequences responsible for melanogenesis (tanning) while retaining the MC3R/MC4R agonist activity responsible for the sexual response.

In June 2019, PT-141 received FDA approval under the brand name Vyleesi (manufactured by AMAG Pharmaceuticals, later Covis Pharma) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity.

PT-141 represents one of the few peptides to achieve full FDA approval for a therapeutic indication, making it a notable success in the peptide therapeutics space.

Structure

PT-141 is a cyclic heptapeptide with the following structure:

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

• Molecular formula: C₅₀H₆₈N₁₄O₁₀
• Molecular weight: 1,025.18 g/mol
• CAS Number: 189691-06-3

Structural features:

• Cyclic structure — lactam bridge between Asp and Lys side chains provides conformational rigidity and enhanced receptor selectivity
• Nle (norleucine) — replaces the methionine found in the parent compound alpha-MSH, preventing oxidative degradation
• D-Phe — D-amino acid substitution enhances protease resistance
• Ac (acetyl) N-terminus — capping prevents aminopeptidase degradation

PT-141 is structurally derived from Melanotan II by metabolic truncation. The active pharmacophore — the His-D-Phe-Arg-Trp core — is shared between PT-141, Melanotan II, and alpha-MSH.

Mechanism of Action

MC3R/MC4R Agonism

PT-141 activates melanocortin receptors 3 and 4 in the central nervous system, particularly in:

• Hypothalamus — the paraventricular nucleus (PVN) and medial preoptic area (MPOA), regions critical for sexual arousal and desire
• Limbic system — areas involved in reward, motivation, and emotional processing

MC4R activation in the hypothalamus triggers:

• Increased dopaminergic signaling in mesolimbic pathways
• Oxytocin release from the paraventricular nucleus
• Activation of descending spinal pathways that modulate genital arousal responses

Central vs. Peripheral Mechanism

The critical distinction between PT-141 and PDE5 inhibitors is the site of action:

• PT-141 acts centrally (brain) to modulate sexual desire and arousal at the neurochemical level
• PDE5 inhibitors act peripherally (genital vasculature) to facilitate erection through increased blood flow
• PT-141 addresses the "wanting" component of sexual response; PDE5 inhibitors address the mechanical/vascular component

This central mechanism means PT-141 can produce pro-sexual effects even in the absence of physical stimulation, which PDE5 inhibitors cannot.

Erectile Response in Males

In male studies, MC4R activation by PT-141 produces erections through a central mechanism involving:

• Hypothalamic oxytocin release
• Activation of sacral parasympathetic outflow
• Increased penile blood flow secondary to central signaling (not direct vascular relaxation)

This mechanism was demonstrated in clinical trials where PT-141 produced erections in men who had failed to respond to PDE5 inhibitor therapy.

Research Summary

Pharmacokinetics

• Half-life: Approximately 2.7 hours
• Onset of action: 30–45 minutes (as-needed dosing)
• Duration of effect: 6–12 hours (subjective pro-sexual effects)
• Peak plasma concentration (Tmax): ~1 hour post-subcutaneous injection
• Bioavailability: ~100% via subcutaneous injection
• Approved dose: 1.75 mg subcutaneous (Vyleesi)
• Maximum frequency: No more than once in 24 hours; no more than 8 doses per month (FDA label)
• Metabolism: Hepatic; multiple metabolites identified
• Excretion: Primarily renal
• Food interaction: No significant food effect on pharmacokinetics

Notable Adverse Effects (from FDA Label)

• Nausea: ~40% incidence at approved dose; most common reason for discontinuation
• Flushing: ~20% incidence
• Headache: ~11% incidence
• Blood pressure: Small transient increases (contraindicated in uncontrolled hypertension)
• Skin hyperpigmentation: Focal darkening at injection site or face reported with repeated use (melanocortin pathway effect)

Dosing Protocols

PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Research/Clinical Dosing

• Dose: 1.0–2.0 mg subcutaneous injection
• Timing: 45 minutes before anticipated activity
• Frequency: As needed, maximum once per 24 hours
• Maximum: No more than 8 doses per month (FDA guidance for Vyleesi)
• Common side effects: Nausea (40%), flushing, headache — typically mild and transient
• Note: Effects can last 12–72 hours in some individuals

Common Discussion Topics

1. Male vs. female applications — While FDA-approved only for female HSDD, PT-141's effects on male erectile function were documented in Phase II trials. Off-label male use is widely discussed, particularly for ED cases unresponsive to PDE5 inhibitors.

2. Nausea management — The 40% nausea rate is the most discussed adverse effect. Strategies including lower dosing, anti-nausea pre-treatment, and gradual dose escalation are common community topics.

3. Comparison with Melanotan II — PT-141 is derived from Melanotan II and shares its pro-sexual effects but without significant tanning activity. Community discussion often compares the two for sexual function applications.

4. Central mechanism implications — The fact that PT-141 works through brain melanocortin receptors rather than peripheral vasculature generates discussion about its potential for treating desire disorders vs. arousal/mechanical disorders.

5. Dosing frequency limits — The FDA label limits use to 8 doses per month, which raises questions about chronic or more frequent use patterns discussed in community settings.

6. Skin darkening — Despite being designed to minimize melanogenic effects, some users report focal skin darkening with repeated use, reflecting residual MC1R activity.

Related Compounds

• Melanotan II — the parent compound from which PT-141 was derived; retains tanning, appetite, and sexual effects
• Afamelanotide (Melanotan I) — a linear MC1R agonist approved for erythropoietic protoporphyria; primarily melanogenic with minimal sexual effects
• Alpha-MSH — the endogenous melanocortin from which the entire family of synthetic analogs derives
• Flibanserin (Addyi) — an FDA-approved oral daily medication for female HSDD; acts on serotonin receptors (5-HT1A/5-HT2A) rather than melanocortins
• Setmelanotide (Imcivree) — an FDA-approved MC4R agonist for rare genetic obesity conditions; demonstrates the therapeutic potential of the melanocortin pathway